lundi 20 août 2018

Onco Actu du 20 août 2018

1. Biologie

Reading between the lines [Nature]

Cancer cell lines evolve in ways that affect how they respond to drugs [Broad Institute]

1.1 Biologie - Gènes

The ‘Zombie Gene’ That May Protect Elephants From Cancer [NY Times]

Elephants Have a Secret Weapon Against Cancer [The Atlantic]

2. Etiologie

Modern myths about cancer – from ‘chemicals’ in food to wifi [The Guardian]

2.11 Etiologie - Alimentation

Should Coffee Come With Cancer Warnings? California Says No [NY Times]

2.6 Etiologie - Environnement

Glyphosate on Trial [McGill Office for Science and Society]

Courts don’t determine scientific facts [The Logic of Science]

With Defenders Like These, The International Agency for Research on Cancer Hardly Needs Enemies [Forbes]

Monsanto ordered to pay $289m as jury rules weedkiller caused man's cancer [The Guardian]

Monsanto Roundup appeal has uphill climb on 'junk science' grounds: legal experts [Reuters]

Monsanto ordered to pay $289 million in world's first Roundup cancer trial [Reuters]

Glyphosate and cancer – revisited [A Plant Out of Place]

3.1 Prévention - Tabac

Statement from FDA Commissioner Scott Gottlieb, M.D., on significant public health value and cost savings resulting from the agency’s youth smoking prevention campaign [FDA]

3.1.1 Prévention - Tabac - e-cigs

Vaping 'can damage vital immune system cells' [BBC News]

Relaxing vaping laws would cut smoking deaths, say MPs [The Guardian]

Adult smokers more apt to use e-cigarettes than nonsmokers [Reuters]

3.4 Chimioprévention

Vitamin D, the Sunshine Supplement, Has Shadowy Money Behind It [NY Times]

4. Dépistage, diagnostic et pronostic

Doctors should avoid saying ‘cancer’ for minor lesions – study [The Guardian]

Overdiagnosis in primary care: framing the problem and finding solutions [BMJ]

4.10 Dép., diag. & prono. - Poumon

Doctors may not explain pros, cons of lung cancer screening [Reuters]

4.12 Biopsies liquides

Blood test could detect kidney cancer up to 5 years earlier [Cancer Research UK]

4.5 Dép., diag. & prono. - Colorectal

Bowel cancer screening to start earlier at age 50 in England [BBC News]

4.9 Dép., diag. & prono. - Sein

Dense breast tissue can complicate mammograms. Women need to know if they have it [STAT]

5. Traitements

Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer [NIH]

Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma [Oncology Nurse Advisor]

The Intelligent Knife: A Potential ‘Game-Changer’ For Cancer Surgery [Cancer Research UK]

5.1 Traitements - Pré-clinique

Breast cancer vulnerability could point way to new target treatments [Institute of Cancer Research]

5.10 Traitements - Essais

FDA Advances Efficient Approaches to Designing and Conducting Cancer Clinical Trials [FDA Voice]

FDA drafts guidance on seamless clinical trials for cancer drug developers [EndPoints]

5.12 Immunothérapies

FDA-AACR Workshop on Non-clinical Models for Safety Assessment of Immuno-oncology Products [AACR]

5.12.1 Immunothérapies - partenariats

Regeneron And Bluebird Team Up To Invent New Cell Therapies For Cancer [Forbes]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Armored CAR-Ts? Memorial Sloan Kettering engineers CAR-T loaded with checkpoint inhibitors [EndPoints]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb's Opdivo secures a lung cancer niche with small-cell green light [FiercePharma]

Bristol Nabs Immunotherapy’s First FDA Nod for Small Cell Lung Cancer [Xconomy]

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer [BMS]

In a landmark OK, FDA green-lights Bristol-Myers’ Opdivo for a niche group of metastatic lung cancer patients [EndPoints]

5.12.8 Immunothérapies - Economie

Outspoken researcher Peter Bach urges CMS to consider ways of bringing down CAR-T prices — and offers a few suggestions [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

How are new medicines approved by EMA? [EMA]

5.3.4 Traitements - AMM (FDA, EMA,...)

China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer [Roche]

Eisai and Merck Announce FDA Approval of LENVIMA® (lenvatinib) Capsules for First-line Treatment of Unresectable Hepatocellular Carcinoma (HCC) [Merck]

FDA approves treatment for two rare types of non-Hodgkin lymphoma [FDA]

FDA Approves New Treatments for Several Rare Cancers [Cancer Research Catalyst]

Months after teaming up on RTK inhibitor Lenvima, Eisai/Merck win new FDA OK in liver cancer [EndPoints]

Roche's Alecensa latest beneficiary of faster China drug approvals [Reuters]

5.4 Traitements - Economie

NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery [Pharma Times]

Japan's Eisai sets price tag of about $17,000 on liver cancer drug [Reuters]

6. Lutte contre les cancers

Aretha Franklin Died From Pancreatic Neuroendocrine Tumor, Not Pancreatic Cancer. There Is A Difference [Dr. Len]

The Agonizingly Slow Progress Against The Cancer That Killed Aretha Franklin [Forbes]

6.1 Observation

Brain tumors occur often in kids with common genetic syndrome [WUSTL]

Thousands of cancer patients face NHS treatment delays [The Guardian]

Tumor Necrosis Factor Inhibitors and Cancer Relapse [Annals of Internal Medicine]

6.12 Ethique

The case against shared decision-making – 2 [Alert and Oriented]

6.3 Associations/Fondations

Two Cancer Research Organizations Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation [ASCO]

6.6 Publications

Prominent health policy researcher plagiarized colleagues’ work, Dartmouth investigation finds [STAT]

6.7 DMP, Big Data & applis

Gigantic review of German science recommends more data and diversity [Nature]

6.7.1 IA/bioinformatique

IBM Watson And The Precarious Balance Between Medicine And Marketing [Forbes]

What Went Wrong With IBM’s Watson [Slate]

6.9 Controverses

Top geneticist loses £3.5-million grant in first test of landmark bullying policy [Nature]

Top cancer scientist loses £3.5m of funding after bullying claims [The Guardian]